The recent clearance brings the Delaware, US-based company’s total FDA-cleared CT scan algorithms to five. Image credit: Shutterstock/Triff.

Annalise.ai’s portfolio of artificial intelligence (AI)-powered triage software has expanded, after the US Food and Drug Administration (FDA) cleared the company’s obstructive hydrocephalus radiological software.

The 510(k) clearance, which is for the triage and notification of the brain condition on non-contrast brain CT scans, means radiology professionals can now have assistance from the software in prioritising patients suspected with obstructive hydrocephalus.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The tool uses algorithms to assist clinicians in identifying suspected critical findings on non-contrast head CT studies and help optimise radiology workflow. 

Obstructive hydrocephalus occurs when there is an accumulation of cerebrospinal fluid along the passages between brain ventricles.  It is a potentially life-threatening condition.

The FDA, seeing the necessity for accurate and quick triaging tools for the condition, also granted the software breakthrough device designation. Annalise.ai said this is the first radiology triage device to receive this accolade.

The recent clearance brings the Delaware, US-based company’s total FDA-cleared CT scan algorithms to five. The algorithms reside on its Enterprise CTB platform, which the company states can detect up to 130 radiological findings.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Annalise.ai also has five FDA-cleared tools for chest X-rays, meaning the company possesses 10 FDA clearances in total.

AI use in medical imaging is transforming clinical workflows by significantly increasing the throughput of image processing and assisting clinicians in identifying areas of interest – leading to quicker patient prioritisation.

According to a report by GlobalData, global revenue for AI platforms across healthcare will reach $4.3bn by 2024. The CAGR between 2019 and 2024 will be 24.6% and 20.6% in healthcare and medical devices respectively.

Dr Rick Abramson, chief medical officer at Annalise.ai, added: “Our advanced algorithms support radiologists by facilitating prioritization of non-contrast head CT studies with suspected critical findings, thereby optimizing radiology workflow. With its set of clearances, Annalise.ai promotes faster report turnaround times by identifying and elevating critical cases for immediate attention.”